BRAINSTORM CELL THERAPEUTICS INC. Retained Earnings
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) had Retained Earnings of -$242.93 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$242.93M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$239.07M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$236.94M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$234.51M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$242.93M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$239.07M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$236.94M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$234.51M 10-Q · filed 2025-11-14 |
| 2025-03-31 | -$229.50M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$226.64M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$223.66M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$220.96M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$218.41M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$215.01M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$209.44M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$208.21M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$202.88M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$197.82M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$192.80M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$185.94M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$178.90M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$173.54M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$167.35M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$162.02M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$155.75M 10-Q · filed 2021-04-26 |
| 2020-12-31 | -$149.09M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$137.27M 10-Q · filed 2020-10-15 |
| 2020-06-30 | -$132.78M 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$125.39M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$117.28M 10-K · filed 2021-02-04 |
| 2019-09-30 | -$109.58M 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$103.95M 10-Q · filed 2019-08-13 |
| 2019-03-31 | -$99.05M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$94.02M 10-K · filed 2020-02-18 |
| 2018-09-30 | -$88.64M 10-Q · filed 2018-10-29 |
| 2018-06-30 | -$85.46M 10-Q · filed 2018-07-23 |
| 2018-03-31 | -$82.37M 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$80.08M 10-K · filed 2019-04-01 |
| 2017-09-30 | -$80.35M 10-Q · filed 2017-10-17 |
| 2017-06-30 | -$77.95M 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$76.91M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$75.12M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$74.50M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$72.89M 10-Q · filed 2016-08-11 |
| 2016-03-31 | -$71.93M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$70.14M 10-K · filed 2017-03-29 |
| 2015-09-30 | -$68.76M 10-Q · filed 2015-11-16 |
| 2015-06-30 | -$66.15M 10-Q · filed 2015-08-13 |
| 2015-03-31 | -$63.89M 10-Q · filed 2015-05-14 |
| 2014-12-31 | -$61.65M 10-K · filed 2016-03-09 |
| 2014-09-30 | -$58.92M 10-Q · filed 2014-11-13 |
| 2013-12-31 | -$52.41M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |